CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Alginatesdrug
Likely dose
Alginates 10mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03193216
NCT03193216Phase 2Completed
CompareCT.gov

The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus: A Pilot Study

Medical University of South Carolina·interventional·Posted Jun 20, 2017·Updated Mar 8, 2023

In Brief

A Phase 2 clinical trial evaluating Alginates for Barretts Esophagus With Dysplasia. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This study evaluates the addition of an alginate based solution to twice daily proton pump inhibitor therapy (PPI) in patients undergoing ablative therapy for dysplastic Barrett's esophagus. The investigators hypothesize that the addition of this medication will help to achieve complete remission of Barrett's over a shorter period of time.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBarretts Esophagus With Dysplasia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 20, 2017
Enrollment StartAug 25, 2017
Primary CompletionJan 1, 2022
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 9.0 years ago

Interventions

Alginatesdrug

Liquid Alginate therapy will be added to twice daily PPI regimen. Patients will be asked to take the alginate solution four times daily (following meals and at bedtime) at 10ml/dose.